【SPARK Taiwan Office】Global SPARK online course - SPARK Lecture
今年由Global SPARK舉辦的線上課程，首次將於美加時間 10 月 2 日（三）17:30 舉行
本次邀請了三位講師進行主題講座
Dr. Justin Sonnenburg, Dr. Sean Spenser, and Dr. Weston Whitaker
“Targeting the Gut Microbiome: Unprecedented opportunities and challenges”
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Dr. Justin Sonnenburg, Dr. Sean Spenser, and Dr. Weston Whitaker
“Targeting the Gut Microbiome: Unprecedented opportunities and challenges”
以下轉知 Global SPARK 的主題講座資訊
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Dr. Justin Sonnenburg, Dr. Sean Spenser, and Dr. Weston Whitaker
will be presenting:
“Targeting the Gut Microbiome: Unprecedented opportunities and challenges”
Justin Sonnenburg, PhD, is the Alex and Susie Algard Endowed Professor in the Department of Microbiology and Immunology at the Stanford University School of Medicine, where he studies the gut microbiota in health and disease and co-directs the Center for Human Microbiome Studies.
He has received an NIH Director’s New Innovator Award and Pioneer Award, the AGA Research Mentor Award, and co-founded Interface Biosciences. He and his wife and collaborator, Erica, are the authors of the book The Good Gut: Taking Control of Your Weight, Your Mood, and Your Long-Term Health.
Sean Spencer, MD, PhD is a Gastroenterologist and Physician Scientist at Stanford University working to uncover the role of dietary intake and the gut microbiome in gastrointestinal disease. Sean obtained his medical degree University of Pennsylvania, earning his PhD studying nutritional immunology with Yasmine Belkaid, PhD at the National Institutes of Health (NIH), after which he moved to Boston for residency training at Massachusetts General Hospital and completed his Gastroenterology training at Stanford University.
Sean has launched a microbiome-focused clinical practice at Stanford where he employs novel diagnostic and therapeutic modalities to better understand and treat his patients with GI disease.
Weston Whitaker, PhD has a primary focus on engineering therapeutic gut commensals. He received his PhD from UC Berkeley, engineering signaling pathways in E. coli, co-advised by John Dueber and Adam Arkin. In his postdoc in Justin Sonnenburg's lab, he developed genetic tools for gut commensal Bacteroides. Based on this work, he started Novome Biotechnologies, a cell therapy company, with co-founders from the Sonnenburg and Dueber labs, to develop a Bacteroides engineered to utilize porphyran for engraftment and biocontainment and to break down oxalate for the treatment of enteric hyperoxaluria (EH).
He has since returned to Dr. Sonnenburg's lab to write up and continue to develop the Novome platform, while pursuing next steps in developing microbial cell therapies, investigating synthetic biology design principles in the context of therapeutic applications and using genetic tools to study microbial ecology and host-microbe interactions.